White label ELPA - ClinicalTrials.eu

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Recruiting

3 1
Investigated Diseases:
- Narcolepsy
Investigated Drugs:
- Alks 2680
+5
Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

Recruiting

2 1 1
Investigated Diseases:
- Interstitial lung disease
- Pulmonary hypertension
Investigated Drugs:
- TX000045
Randomized Controlled Trial Assessing Dermal Bioequivalence of Two Doxepin Hydrochloride Creams in Healthy Volunteers

Recruiting

1 1 1 1
Safety and Pharmacokinetic Dose-Escalation Study of IMC-S118AI and Sodium Chloride in HLA‑A*02:01‑Positive Participants with Type 1 Diabetes

Recruiting

1 1 1
Investigated Diseases:
- Type 1 diabetes mellitus
Investigated Drugs:
- Sodium Chloride
Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Recruiting

3 1 1
Investigated Drugs:
- Depemokimab
+3
A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

Recruiting

1 1 1

+3
Early switch to oral amoxicillin (drug combination) for adults with vertebral osteomyelitis: a randomised non‑inferiority trial

Recruiting

3 1 1 1
Investigated Drugs:
A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Recruiting

2 1 1
Investigated Diseases:
- Myasthenia gravis
Investigated Drugs:
- Empasiprubart
- Efgartigimod Alfa
+1
Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Recruiting

2 1 1 1
Investigated Drugs:
+1
Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Recruiting

3 1 1 1
Investigated Drugs:
- Cabozantinib
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies